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2Introduction
Diabetes mellitus, a metabolic disorder characterised by high levels of blood glucose, is
associated with several vascular complications. Although insulin treatment, oral medications,
dietary regulations and exercise can delay the development of diabetic microangiopathy [1],
the development of macroangiopathy cannot be prevented solely by glycaemic control [2].
Diabetic retinopathy and nephropathy leading to blindness and renal failure are the hallmarks
of microangiopathy. However, diabetic-macroangiopathy refers mainly to an accelerated form
of atherosclerosis. This in turn affects both the coronary and cerebral vasculature, thus
increasing the risk of myocardial infarction, angina pectoris and cerebrovascular accidents.
Indeed, coronary heart disease and peripheral vascular disease are the leading causes of
morbidity and mortality in diabetes mellitus [3]. Diabetes mellitus in humans [4,5] and animal
models of diabetes [6,7] are associated with impaired endothelium-dependent relaxation i.e.
endothelial dysfunction. The term “endothelial dysfunction” in fact refers to impairment of
many significant functions of the endothelium including anti-inflammatory and anti-
proliferative characteristics as well as vasodilatation [8,9]. However, in many scientific
publications it is solely used to describe impaired endothelium-derived vascular relaxation that
may develop secondary to hypertension, atherosclerosis or hyperglycaemia. In this review the
term endothelial dysfunction, a surrogate marker for the development of diabetic
macroangiopathy, will be used in the same context. Several factors including increased
synthesis of vasoconstrictor agents through the cyclooxygenase (COX) pathway [10] and
dysregulation of the gene encoding endothelial type of nitric oxide synthase (eNOS) [11,12] in
endothelium have been proposed to account for this defect in diabetes. However, in recent
years, reduced bioavailability of nitric oxide (NO), the most important endogenous vasodilator
agent, due to excessive synthesis/release or diminished destruction of reactive oxygen species
(ROS) [13-15] has been implicated in the pathogenesis of this defect. The purpose of this
review is therefore to summarise the mechanisms whereby vascular cells produce NO and
ROS, to examine molecular and pharmacological mechanisms underlying the pathogenesis of
diabetic endothelial dysfunction with particular reference to reactions between ROS and NO,
and finally to discuss the reversal of diabetic endothelial dysfunction.
Vascular endothelium
The endothelium, once considered a simple monolayer of cells covering the entire inner
surface of all the blood vessels, has recently been established as a strategically-located
multifunctional organ. It lies between circulating blood and the vascular smooth muscle and
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in the maintenance of blood fluidity and homeostasis. To perform such a wide range of
functions, the endothelium synthesises or releases several vasoactive substances, including the
vasodilators NO, prostacyclin and endothelium-derived hyperpolarising factors (EDHFs) and
the vasoconstrictors angiotensin II and endothelin-1. Under physiological conditions, the
endothelium acts as an inhibitory regulator of vascular contraction, leukocyte adhesion,
vascular smooth muscle cell growth and platelet aggregation [16]. However, the characteristics
of the endothelium change in response to local or systemic changes such as trauma,
hyperglycaemia or dyslipidaemia and dysfunction of endothelium is considered present when
normal organ function can no longer be preserved either in the basal state or in response to any
given physical, humoral or chemical stimuli.
Nitric Oxide (NO)
NO is generated along with L-citrulline from the cationic amino acid L-arginine by a class
of enzymes known as nitric oxide synthases (NOSs) in the presence of molecular oxygen and
NADPH [17,18]. NOSs contain both flavin adenine dinucleotide (FAD), flavin
mononucleotide (FMN) and require several co-factors including tetrahydrobiopterin (H4B) and
reduced glutathione for activity [19,20]. Three isoforms of NOSs have so far been identified all
of which are the products of separate genes which share approximately 60% homology at
amino acid level [21]. NOSs are divided into two classes with regard to the nature of their
expression and requirement of Ca2+ for their enzymatic activity. Both endothelial type (eNOS
or NOS3) and neuronal type (nNOS or NOS1) NOS are constitutively expressed and Ca2+-
dependent while the inducible type (iNOS or NOS2) is expressed in response to several stimuli
including cytokines and does not require Ca2+ for its activity. It is important to note in this
context that, although NOS3 is constitutively expressed, many patho-physiological stimuli
regulate its expression. Indeed, chronic fluid shear stress [22], exercise [23] and sex hormones
[24] elicit an increase in NOS3 gene expession while tumor necrosis factor 25 and hypoxia
[26] downregulate its expression at mRNA and/or protein levels. The current data on the
molecular regulation of NOS3 in diabetic animals [11,12] and in endothelial cells grown under
hyperglycaemic conditions suggest a defect in its gene regulation [27]. NOS3 is expressed in
abundance in cardiac myocytes and coronary microvascular endothelial cells and is therefore
considered as the main source of NO within the vascular endothelium [28].
4Endothelium-derived NO is known to be the most potent endogenous vasodilator in the
body. It is synthesised and released by the endothelium in response to a wide range of
chemical, physical and humoral stimuli including thrombin, hormones, local autacoids,
alterations in oxygen tension and shear stress [29,30]. After synthesis NO is released into the
subendothelial space and vascular lumen where it directly causes the underlying vascular
smooth muscle to relax by binding to the heme moiety of soluble guanylate cyclase, thereby
increasing the production of intracellular cyclic 3’-5’-guanosine monophosphate (cGMP) [31]
[Fig. 1]. Endothelial secretion of NO counterbalances the direct vasoconstrictive effects of
norepinephrine, serotonin, angiotensin II and endothelin on the vascular smooth muscle [32].
NO has also been shown to reduce oxygen consumption [33] and plays a critical role in the
pathogenesis of atherosclerosis due to its inhibitory effects on platelet aggregation [34],
leukocyte adhesion [35], DNA synthesis [36] and vascular smooth muscle cell proliferation
[37]. In addition to its roles mentioned above, NO plays a significant role in the regulation of
blood pressure. Indeed, NOS3 gene knock out mice develop severe hypertension and blood
vessels isolated from these mice do not relax when exposed to endothelium-derived
vasodilators such as acetylcholine [38]. It has also been shown that the inhibition of NO
synthesis leads to significant peripheral vasoconstriction and elevation of blood pressure
[39,40] [Table 1].
Oxidative Stress in Diabetes
The term oxidative stress refers to a condition in which cells are subjected to excessive
levels of molecular oxygen or its chemical derivatives called reactive oxygen species (ROS).
Under physiological conditions, the molecular oxygen undergoes a series of reactions that
ultimately lead to the generation of superoxide anion (O2-), hydrogen peroxide (H2O2) and
H2O. Peroxynitrite (OONO-), hypochlorus acid (HOCl), the hydroxyl radical (OH.), reactive
aldehydes, lipid peroxides and nitrogen oxides are considered among the other oxidants that
have relevance to vascular biology. In the vascular endothelium, increases in oxidant stress
may arise due to several mechanisms [Table 2] and are associated with alterations in normal
endothelial functions and are implicated in the pathogenesis of vascular complications in
several disease states including diabetes mellitus (DM). However, the mechanisms underlying
altered endothelium-dependent vascular relaxation in diabetes mellitus have been proposed to
be multifactorial and seem to be dependent on the duration of hyperglycaemic state and
vascular bed being studied. Indeed, ROS may enhance the sensitivity of the contractile
elements to Ca2+ [41] and facilitate the mobilisation of cytosolic Ca2+ in vascular smooth
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transcription factors leading to the upregulation of adhesion molecules to platelets and
leukocytes and decreasing the bioavailability of NO or indirectly by increasing the formation
of advanced glycation end products (AGEs) or increasing oxidation of low density lipoprotein.
O2- is considered to be the most important ROS that directly causes contraction of vascular
smooth muscle cells [43]. It also rapidly scavenges NO within the vascular wall to reduce its
biological half-life [44]. An increase in O2- levels has been reported in both diabetic rat aorta
[14] and more recently endothelial cells grown under hyperglycaemic conditions [15]. The
excess generation of O2- in diabetic vessels has been attributed to increased activity of several
O2--generating enzymes including NOSs. Indeed, it has been suggested that NOSs are able to
generate O2- in a Ca2+-dependent manner particularly in the absence of substrate L-arginine
and cofactor H4B, both of which have been associated with diabetes [45,46]. However,
compelling evidence suggests that NAD(P)H oxidase constitutes the main enzymatic source of
endothelial and vascular O2- in other disease states associated with endothelial dysfunction
such as hypercholesterolaemia [47] and hypertension [48]. It is noteworthy that a recent report
has also linked endothelial dysfunction in the central retinas of an obese and non-insulin
dependent diabetic BBZ/WOR rats to NADH-oxidase mediated oxidative injury [49].
NAD(P)H oxidase is a multicomponent enzyme system which catalyses one electron reduction
of molecular oxygen to O2-. It is predominantly expressed in neutrophils and plays a pivotal
role in non-specific host defence against pathogens by generating large (millimolar) quantities
of O2- during the so-called respiratory burst [50]. The neutrophil enzyme is composed of a
membrane-bound cytochrome b558 [p22-phox and gp91-phox (for phagocyte oxidase)], a
small G protein either (rac1 or rac2) and several cytosolic components (p47-phox, p67-phox
and p40-phox) [50,51]. On activation, the cytosolic components translocate to the plasma
membrane where they tightly associate with the cytochrome b558 to create the active enzyme
[52]. In current models, the full electron transfer activity of the neutrophil NADPH oxidase
resides in the cytochrome b558, which is also critical for enzymatic stability as a whole.
However, the presence of gp91-phox has not been demonstrated in vascular smooth muscle
cells so far, despite the presence of a functional enzyme [53]. The endothelial and vascular
smooth muscle cell NAD(P)H oxidases bear substantial similarities to neutrophil type enzyme
including their non-mitochondrial location, in spite of some functional differences between
them [54,55]. Namely, while endothelial and vascular oxidases appear to be constantly active,
generating low levels of ROS and utilising NADH as a cofactor [55], phagocytic oxidase is
activated in response to stimulation, generates high levels of ROS and preferentially uses
6NADPH as a cofactor (hence the term NAD(P)H oxidase or NADH/NADPH oxidase) [56]. A
recent report has indicated that these functional differences may be attributed (-at least in
endothelial cells-) to different glycosylation patterns and mutations in NADPH binding as well
as so called non-functional domains in endothelial oxidase [57]. Similar to endothelial cells,
vascular smooth muscle cell function is also regulated by reactive oxygen species in both a
paracrine and autocrine fashion. In vivo, smooth muscle cells produce O2- and H2O2 [48,58]
and are exposed to free radicals released by circulating blood cells, inflammatory cells, and
endothelial cells. Vascular smooth muscle cell-associated reactive oxygen species also derive
mainly from an NAD(P)H oxidase. Indeed, an O2--generating NAD(P)H oxidase in pulmonary
arteries that is modulated by hypoxia and is based on a cytochrome b558 electron transport
system has recently been reported [54]. In support of this finding, another study has also shown
that NAD(P)H-dependent O2- production in vascular smooth muscle cells is induced by
angiotensin II and tumour necrosis factor- [53]. The activity of vascular oxidase similar to
endothelial cells is also inhibited by the flavoprotein inhibitor diphenylene iodonium (DPI)
[55,59]. An identical enzyme has also recently been reported in the media or adventitia of
rabbit aorta [60]. Taken together these data strongly indicate that an NAD(P)H oxidase is the
major source of O2- in endothelial as well as vascular smooth muscle cells. Indeed, the
contribution of other potential O2--generating enzymes including cyclooxygenase, xanthine
oxidase, mitochondrial NADH dehydrogenase and NOSs to overall production of O2- in
endothelial and vascular smooth muscle cells has been found to be minor, as selective
inhibitors of these enzymes did not alter net production in either cell homogenates [55,60].
The increase in O2- levels could also be due to its decreased metabolism as opposed to its
increased generation (or indeed both mechanisms may be responsible). Deficiency or
inactivation of SOD enzymes (intracellular Cu/Zn- or Mn- and an extracellular Cu/Zn-
containing isoforms) which dismutate O2- to hydrogen peroxide (H2O2) elevate O2- levels in
intact blood vessels. SODs therefore may be critical in the pathogenesis of endothelial
dysfunction in several pathological conditions including DM. However the exact role of SODs
in the regulation of vascular tone and in the development of endothelial dysfunction is not
known and the currently available related data are somewhat conflicting. Indeed, reports have
suggested that SODs are both crucial [61,62] or ineffective [63,64] in the protection of NO in a
variety of blood vessels. A recent study has demonstrated that the adenovirus-mediated transfer
of Cu/Zn SOD gene did not improve vascular relaxation in diabetic rabbit carotid arteries [11]
perhaps due to its inefficiency in increasing the amount of SOD in the tunica media in contrast
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localised Cu/Zn SOD may not be able to protect NO from O2- if the reaction between these two
radicals takes place in the extracellular space.
It is important to note that the excess production of H2O2, mediated by the O2-/SOD
pathway, also causes irreversible endothelial damage linked with diminished NO production,
although it initially stimulates NO production [66]. Indeed, homocysteine-induced endothelial
cell injury has been associated with H2O2 and has been reduced by the enzyme catalase [67].
Catalase, a H2O2 scavenger, catalyses the transformation of H2O2 to yield H2O and oxygen.
Several lines of data indicate that the activity of catalase, like SODs, is modulated by many
stimuli and indeed is regulated to compensate for the biological requirements imposed by
increased oxidative stress [68]. An in vivo study designed to investigate the expression of
genes for Cu/Zn SOD and catalase in kidney tissue of rats with chemically induced controlled-
or uncontrolled-diabetes has demonstrated a direct correlation between the levels of blood
glucose and renal mRNA levels of both enzymes. However, while treatment of diabetic rats
with a moderate dose of insulin normalised catalase mRNA levels, it did not have any effect on
Cu/Zn SOD mRNA levels suggesting a different threshold of these genes to different glucose
concentrations [69]. In support of these findings exposure of endothelial cells to high glucose
concentrations has been shown to increase both the activity and the mRNA levels of catalase
and Cu/Zn SOD implying a compensatory effect to neutralise increased free radical generation
in vitro [70].
Glutathione peroxidase (GPx) localised to the cytoplasm is known to be another H2O2
scavenger. It has been shown that intracellular glutathione, a key aqueos phase antioxidant,
levels are decreased in retinal pericytes grown under high (25 mmol/l) glucose concentrations
coupled with the decrease in GPx activity [71]. Another study designed to investigate the link
between increased oxidative stress and impaired free-radical scavenger function in endothelial
cells exposed to high glucose concentrations has revealed a reduced GPx-dependent H2O2-
degradation which may be associated with increased cellular damage elicited by H2O2 [72].
Indeed, high glucose-derived induction of oxidative stress has been reported in several cell
lines including human endothelial cells [73] and porcine aortic vascular smooth muscle cells
[74].
In addition to O2-, hyperglycaemia also stimulates the synthesis of NO via increased
enzymatic activity of endothelial [75] and inducible [76] isoforms of NOS. However, the NO
generated in diabetic vasculature is rapidly scavenged by omnipresent O2- to form peroxynitrite
[OONO-] at a rate of 6.7 x 109 ms-1 [77]. This rate is three times faster than the reaction
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hand potentially deleterious O2- is neutralised, on the other hand the most potent vasodilator
NO is consumed and OONO- is produced as a result [79]. It is therefore easy to comprehend
why OONO- itself has been suggested as both a toxic compound eliciting tissue damage as
well as a protective molecule improving cellular and organ vitality. OONO- has been shown to
increase insulin secretion, DNA damage and cell death in human and rat islets of Langenhars
[80]. It has also been linked to attenuation of vascular responses in diabetic and preeclamptic
human placentas [81]. A recent report has also demonstrated that OONO- contributes to the
destruction of pancreatic islet beta-cells of NOD mice developing autoimmune diabetes,
suggesting that OONO- may play a pivotal role in the initiation of insulin-dependent diabetes
mellitus (IDDM) [82]. A recent in vitro study has also suggested that OONO- may mediate the
apoptotic effects of high glucose on endothelial cells via NFB activation since this induction
of cell death was prevented by an antisense nucleotide to the p65 NFB binding site [83].
OONO- has been shown to nitrosylate substrates such as tyrosine moieties within proteins
thereby leading to organ malfunction [84]. OONO- is also known to cause lipid peroxidation
[85] and depletion of important plasma antioxidants such as glutathione and cysteine [86].
Administration of OONO- impairs relaxation of isolated perfused rat heart [87] and when given
systemically causes vascular dysfunction in rats via selective impairment of adrenoreceptors
[88].
Contrary to its deleterious effects, OONO- also relaxes vascular smooth muscle either
directly or indirectly by triggering intracellular second messenger pathways to increase cGMP
levels. Although the presence of endothelium is not a prerequisite to this relaxation, it
augments the overall relaxation [89]. Recent evidence has suggested that OONO- may actually
preserve its beneficial properties under in vivo physiological conditions when thiol containing
agents such as glutathione, albumin and cysteine are readily available to convert OONO- into
nitrosothiols and other products with antiatherogenic characteristics. However, as a deficiency
of glutathione and other antioxidant agents have been reported in both diabetic patients and
several cell lines including pericytes grown under high glucose media it is tempting to
speculate that OONO- will have no vasodilatory effect in diabetics [74,90].
It has also recently become apparent that free radicals advance endothelial dysfunction by
promoting growth. Indeed, angiotensin II-induced hypertrophy has been linked to excessive
generation of NAD(P)H oxidase-mediated ROS [53]. In the diabetic state, the high levels of
glucose may adversely influence endothelial cell function by increasing the synthesis of
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growth factor (VEGF), and extracellular matrix components such as collagen and fibronectin.
TGF stimulates the accumulation of matrix proteins such as collagens, fibronectin and
proteoglycans both by enhancing their synthesis [91] and by reducing their proteolysis [92].
These effects of TGF are reversed by normalisation of blood glucose levels with insulin
treatment [93] suggesting a significant role for TGF in the matrix alterations in microvessels.
On the other hand, endothelial cells grown under hyperglycaemic conditions show decreased
proliferation and fibrinolytic potential [94] and increased programmed cell death [95].
Cellular mechanisms for the development of diabetic endothelial dysfunction
Non-enzymatic glycation
Another mechanism that may account for hyperglycaemia-derived vascular cell
dysfunction is the spontaneous formation of glucose adducts to basic amino acids [lysine and
arginine] and other amine-containing molecules. Although these early non-enzymatic glycation
products are reversible (like glycohaemoglobin), they later become irreversibly modified
products of glucose called “advanced glycation end-products” or AGEs, via slow and complex
processes including glycation, glycooxidation and auto-oxidative glycosylation [96].
Endothelial cells express receptors for AGEs [97] which facilitate their internalisation and
transfer into the subendothelial space. AGEs may impair endothelium-dependent relaxation
through glycosylation and oxidative modification of LDL which in turn directly inactivates or
disrupts the formation of NO [98]. AGE induced modification of LDL also decreases the
particle clearance [99] from the circulation thereby contributing to an expansion in LDL into
endothelial cells.
Hyperglycaemia
Support for the concept of increased oxidative stress-mediated endothelial dysfunction in
diabetes has derived from both in vitro and in vivo experiments which have suggested that
hyperglycaemia is almost certainly the primary causal factor, mediated through several
mechanisms, including alterations in the cellular redox state by an altered NADH/NAD+ ratio,
changes in the regulation of protein tyrosine kinases, dysregulation of protein kinase C and the
accumulation of sorbitol.
Hyperglycaemia elicits an increase in the intracellular NADH/NAD+ and a decrease in
NADPH/NADP+ ratios through hyperactivity of the sorbitol (polyol) pathway leading to a
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cytosolic redox imbalance i.e. hyperglycaemic pseudohypoxia [100]. This is so called due to
the fact that an increased NADH/NAD+ ratio mimics the effects of tissue hypoxia. Aldose
reductase is the first, and rate-limiting, enzyme in this pathway that catalyses the NADPH-
dependent reduction of glucose to sorbitol which in turn is catalysed to fructose by sorbitol
dehydrogenase [101]. The accumulation of sorbitol which increases intracellular osmolality is
thought to account for polyol pathway-related changes. Extensive studies on aldose reductase
have been conducted to elucidate a causal connection between the activity of this enzyme and
diabetic complications. Various studies have reported a preventive role of aldose reductase
inhibitors on the development of diabetes-like neuropathy [102], myopathy [103,104] and
nephroptahy [104]. However, several lines of data revealed closer links between several
metabolic alterations such as myo-inositol depletion [105], glycation [106], increased oxidative
stress [107] and diabetic complications.
The cellular NADPH pool required for NO generation and to replenish antioxidant
glutathione may also be depleted in diabetes by a hyperactive pentose phosphate pathway
activity in endothelial cells [108], consequently leading to abnormalities in protein tyrosine
kinase activation [109]. Activation of transcription factors by phosphorylation of tyrosine
kinase plays significant roles in gene regulation of vascular cells to increase the production of
extracellular matrix components discussed above.
Hyperglycaemia also alters several biochemical pathways including eicosanoids, protein
kinase C (pKC) activity, long-chain fatty acids and ROS. Activation of several transcription
factors by ROS plays a pivotal role in gene regulation and gene expression of vascular cells.
Increased cellular uptake of glucose stimulates pKC activity which mediates endothelial and
vascular smooth muscle cell functions through regulation of permeability, contractility, blood
flow and basement membrane synthesis and has therefore been associated with several
vascular abnormalities. pKC can modulate the actions of hormones, growth factors and ion
channels such as the Na/proton antiport, a key regulator of intracellular pH, growth,
differentiation and contractility. pKC activation in diabetes has been implicated in the
increases in intracellular diacylglycerol through either de novo synthesis via increased
glycolysis or membrane-associated phosphatidyl inositol 4,5-biphosphate. In a rodent model of
insulin dependent diabetes mellitus an oral inhibitor of the pKC isoforms ameliorated
vascular dysfunction. pKC activity in addition to its aforementioned effects also activates
peroxidase enzymes and the cyclooxygenase pathway thus causing overproduction of oxidative
molecules [110-112].
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Hyperglycaemia is also linked with the activation of coagulation system through its
connections with some of the aforementioned mechanisms namely non-enzymatic glycation
and AGE formation which may decrease antithrombin III activity and increase tissue factor
activity respectively as well as increased oxidative stress [113-115]. It is highly likely that
during later stages of diabetes loss of endothelial anticoagulant properties may further activate
coagulation cascade. Higher levels of a number of coagulation factors such as endothelium-
derived von Willebrand’s factor, fibrinogen and PAI-1, in association with endothelial cell
damage and micro- and macrovascular damage may also contribute to this procoagulant state
[116-118].
Prevention and reversal of diabetic endothelial dysfunction
The close link between hyperglycaemia and endothelial dysfunction is supported by
both in vitro and in vivo studies. The adverse effect of hyperglycaemia on vascular function in
diabetes may be due to the consequences of the impaired L-arginine/NO pathway, oxidative
stress and increased formation of AGEs via non-enzymatic glycosylation. Hence several
therapies have been proposed for preventing and to a certain extent reversing endothelial
dysfunction in diabetic state by directly targeting these pathogenetic mechanisms. It has been
reported that plasma concentrations of basic amino acids (e.g. L-arginine, L-lysine and L-
histidine) are reduced in diabetes and vascular rings obtained from diabetic rats show impaired
endothelium-dependent vasodilatation. In vivo L-arginine treatment of streptozotocin-induced
diabetic rats revealed an increase in the aortic relaxation to acetycholine and also prevented
increases in plasma malondialdehyde levels, suggesting that diabetes-induced functional
abnormalities occurring in rat aortas may in part result from L-arginine deficiency [119]. In
support of this, it has previously been documented that the relaxation of vascular rings from
diabetic animals to acetylcholine is potentiated by pretreatment with L-arginine (but not D-
arginine). This again may imply the involvement of a decrease in L-arginine concentrations
and/or a defect in the utilisation of L-arginine by NOS3 in the pathogenesis of endothelial
dysfunction in diabetes [120]. Similar studies have also suggested a prominent role for H4B
availability in the regulation of NO production by diabetic endothelium, because 6-methyl-
5,6,7,8-tetrahydrobiopterin improved the impaired endothelium-dependent vasodilatation in
some vascular beds of diabetic animals [121].
Antioxidant defences may also be impaired in diabetes thereby contributing to net
oxidative stress [122]. Indeed a variety of defects in serum antioxidant status has been reported
in diabetic patients compared to healthy subjects [123,124]. Hence it has consequently been
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suggested that diabetic patients might benefit from supplementation with antioxidant vitamins
(vitamin C and vitamin E) to prevent free radical oxidation and endothelial dysfunction as a
result [125]. Vitamin C deficiency in diabetes may occur as a result of excessive excretion or
poor diet. An increased oxidation of vitamin C as a result of increased free radical synthesis
[126] and hence increased generation of its oxidation product, dehydroascorbic acid (DHA)
[127] or a decline in the regeneration of vitamin C from DHA may largely be responsible for
this deficiency. The latter may be due to competitive inhibition of vitamin C transport across
the cell membrane via structurally similar glucose [128]. A consistent beneficial effect of
vitamin C has been reported in human subjects and several animal models of human diseases.
Acute intra-arterial administration of vitamin C to patients with diabetes improves
endothelium-dependent vasodilatation to methacholine but not the response to sodium
nitroprusside, a NO donor or to a smooth muscle relaxant [129]. Similarly, physiological
concentrations of vitamin C has been shown to reverse endothelial dysfunction in conduit
arteries of patients with congestive heart failure [130] and angina [131] while intra-arterial
infusion of supraphysiological concentrations of vitamin C has improved microvascular
function in patients with hypertension and hypercholesterolaemia [132]. A recent report has
also shown that vitamin C plays a significant role in the prevention of ROS production by
scavenging O2- and apoptosis in the early stages of incubation of endothelial cells with high
glucose [133]. The protective effects of antioxidants vitamin C and taurine have also been
recently reported on renal injury in streptozotocin-induced diabetic rats in that these agents
reduced albuminuria, glomerular hypertrophy, glomerular collagen and TGF-1 accumulation
[134]. Administration of vitamin E has also been shown to have similar effects to these
antioxidants in the early phase of glomerular injury. However, studies of chronic treatment
with vitamin E are still needed as chronic dietary supplementation of vitamin E to diabetic rats
has been attended with higher mortality rates [135].
It is difficult to understand how vitamin C can act as an effective antioxidant in high risk
(and high oxidative stress) patients considering very slow reaction rate between vitamin C and
O2- compared to NO and O2- [136]. However, recent studies have suggested that vitamin C
may improve the bioavailability of NO by regulating cellular redox state and also sparing
intracellular glutathione from oxidation which may be important for NO in humans [137,138].
Vitamin E is the major lipid-soluble antioxidant, taken up by low-density lipoprotein
(LDL) particles, which may improve endothelial function. Indeed, vitamin E supplements
reduce the sensitivity of LDL to in vitro oxidation in healthy subjects as well as Type 2
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diabetics [139] which suggests that endothelial function may be improved due to a reduction in
the availability of oxidised LDL in diabetic vessels [140]. Vitamin E in addition inhibits
glucose-induced protein kinase C II activation in vascular smooth muscle cells [141]. Protein
kinase C II induction has been implicated in vasoconstrictive effects of several hormones such
as angiotensin II [111]. It has been shown in animal models of diabetes that vitamin E
treatment improves coronary and aortic vascular endothelial function and prevents diabetes-
induced abnormalities [142,143] although the opposite has been reported in mesenteric
arterioles [144]. In contrast to the consistent beneficial effects observed in animal models, the
results in humans have been mixed. One randomised study, the Cambridge Heart Antioxidant
Study (CHAOS), demonstrated a marked reduction in non-fatal myocardial infarction in
patients randomised to treatment with 400-800 IU of vitamin E/day compared to patients
receiving placebo [145]. However, many subsequent studies including the Heart Outcomes
Prevention Evaluation (HOPE) have failed to confirm these findings and revealed no beneficial
effect of vitamin E on the prevention of cardiovascular disease after 4.5 years of use [146].
The species differences and the phase of the disease may account for different results
obtained from animal and human studies. Indeed, majority of the experimental studies
investigated the bioavaliability of endothelium-derived NO or endothelium-derived vascular
relaxation following treatment with vitamin E alone or in combination with vitamin C or -
carotene imminently after the onset of diabetes following streptozotocin or alloxan injections
or initiation of hypercholesterolaemic diet. In contrast, the current human data have been
obtained from patients with longstanding risk factors and/or proven coronary artery disease
and peripheral vascular disease [147,148]. The vascular bed being studied may also have
implications in inconsistent human results, namely, most of the studies carried out in human or
animal conduit arteries have shown a beneficial effect while studies performed on human
forearm i.e. microvessels have not revealed any beneficial effects [149,150].
Increased superoxide may however directly inactivate NO with the formation of the highly
toxic oxidant, peroxynitrite. Endothelial dysfunction not only occurs in overt diabetes but can
also be induced by simple exposure of isolated vessels to high glucose media in vitro [151].
Pretreatment of rat aorta with SOD produces significantly greater relaxations in aortic rings
incubated in high glucose [14]. Likewise pretreatment with SOD plus catalase or an inhibitor
of hydroxyl radical formation (DETAPAC) has been shown to improve endothelial
dysfunction in aortic rings of streptozotocin-induced diabetic rats suggesting that vascular
production of both O2- and hydroxyl radicals may contribute to endothelial dysfunction in this
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model [152]. However, elevated ambient glucose concentrations in diabetes mellitus may
result in glycosylation of native superoxide dismutase leading to impairment of its enzymatic
activity [153].
In addition, the changes in intracellular cell signalling may impair appropriate activation
of NOS in response to neurohumoral or mechanical stimuli. Indeed, several recent studies
strongly indicate the involvement of the pKC pathway in vascular complications in diabetes.
High concentrations of glucose strongly increase the intracellular levels of diacylglycerol
which consequently lead to protein kinase C activation. In vitro hyperglycaemic endothelial
dysfunction caused by incubation of vascular rings with high concentrations of glucose has
been corrected with pKC inhibitors [154]. These in vitro observations have also been
supported by in vivo studies demonstrating that therapy with pKC inhibitors ameliorated
vascular complications in diabetic rats [112]. Although, the mechanisms underlying pKC-
mediated endothelial dysfunction remain poorly understood, in vitro experiments have shown
that NOS3 activity is diminished through phosphorylation of the NOS3 gene [155] and O2-
production is enhanced by pKC activation [75].
A weak glutathione-related antioxidant defence, i.e. diminished enzymatic activities of
glutathione peroxidase, glutathione reductase and in part glutathione transferase, is present in
human atherosclerotic lesions [156] while intracoronary infusion of reduced glutathione
improves endothelial vasomotor response to acetylcholine in human coronary circulation
[157]. Furthermore, L-2 oxothiazolidine-4-carboxylic acid, which augments intracellular
glutathione, improves endothelium-dependent relaxation in patients with coronary artery
disease [158]. The instant improvement of NO availability following administration of
antioxidants supports the role of ROS in the impaired endothelium-dependent relaxation in
coronary artery disease and its risk factors and is consistent with the notion that the cellular
redox state may be an important regulator of endothelium-derived NO.
In recent years gene therapy studies have been conducted to reverse the immune-mediated
destruction of the pancreatic beta cells in case of type I diabetes. Insulin gene delivered via a
retroviral vector to the liver improved fasting glucose levels in streptozotocin-diabetic rats, but
had little effect on glucose levels after feeding [159]. However, this approach is at present far
from application in humans because physiologic regulation of insulin production and release in
response to blood glucose levels over minutes has not yet been accomplished.
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Conclusions
The endothelium is an important locus of control of vascular functions. Several diseases
including diabetes are associated with impaired endothelial function. Although, several factors
including dysregulation of NOS gene, deficiencies of either substrate i.e. L-arginine or cofactor
namely tetrahydrobiopterin for physiological NOS activity and excessive release of
endothelium-derived vasoconstrictors such as prostaglandins have been implicated in the
pathogenesis of impaired endothelium-dependent relaxation in diabetes, a single unifying
mechanism has yet to emerge. However, several lines of evidence including the activation of
transcription factors in particular NFB, overexpression of growth factors and activation of
protein kinase cascades suggest that in the initial stages of diabetes multiple pathways may
converge to increase reactive oxygen species and a diabetes-induced oxidative stress [Fig. 2].
This may arise from enhanced generation of free radicals as a consequence of glucose
autooxidation or pseudohypoxia. This may also arise from the overexpression of superoxide
anion-generating enzymes as well as deficiency of free radical-metabolising enzymes. A form
of oxidative stress as a direct consequence of interactions between NO and oxygen-derived
radicals represents a common pathological mechanism in risk factors for atherosclerosis
including hypertension, hypercholesterolaemia and diabetes.
The mechanisms whereby endothelial and vascular cells produce ROS are only presently
coming to light and almost certainly will prove to be a focus for better-targeted future
therapeutic strategies to reverse of endothelial dysfunction.
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Figure legends
Fig. 1. Activation of endothelial cells by a variety of stimuli can stimulate the eNOS to convert
amino acid L-arginine into NO and L-citrulline. NO in turn causes relaxation of underlying
vascular smooth muscle cells by increasing the formation of cGMP from GTP by sGC. NO,
nitric oxide; eNOS; endothelial nitric oxide synthase; GTP, guanosine triphosphate; sGC,
soluble guanylate cyclase.
Fig. 2. Pathogenesis of endothelial dysfunction in diabetes mellitus through hyperglycaemia-
induced oxidative stress. Hyperglycaemia elicits oxidative stress by directly impairing the
cellular mechanisms (on the left) which in turn elicits endothelial dysfunction. Hyperglycaemia
also induces the excess generation of NO and O2- through activation of NOSs and NAD(P)H
oxidase respectively. O2- reacts with NO to produce OONO-, another oxidant that increases
oxidative stress and elicits endothelial dysfunction by promoting tissue injury. O2- is converted
to H2O2 by SODs which not only increases oxidative stress but also generates endothelial
dysfunction by modulating intracellular signalling and transcription factors. NO, nitric oxide;
eNOS, endothelial NO synthase; iNOS, inducible NO synthase; O2-, superoxide anion;
OONO-, peroxynitrite; H2O2, hydrogen peroxide; SOD, superoxide dismutase; AGE, advanced
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Table 1. Functions of endothelium-derived NO
 Maintenance of normal vascular smooth muscle tone
 Inhibition of vascular smooth muscle cell proliferation
 Modulation of inflammatory and immune responses
 Regulation of endothelial integrity and vascular permeability
 Inhibition of leukocyte migration and adhesion
 Inhibition of platelet adhesion and aggregation
 Inhibition of LDL oxidation
 Suppression of endothelin production
 Regulation of blood pressure
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Table 2. Potential causes of increased oxidative stress in diabetes mellitus
 Diminished expression/activity of eNOS and generation of NO,
 Overproduction of ROS in particular O2- by NOSs or NAD(P)H oxidase
 Impaired expression/activity of SODs
 Decreased antioxidant enzyme capacity i.e. catalase and glutahione peroxidase
 Reduced levels of antioxidants glutathione, -tocopherol, ascorbate
 Enhanced protein glycosylation and AGE formation
 Enhanced glucose autooxidation
 Hyperactivity of the sorbitol (polyol) pathway
